Loading...
XSHE
002370
Market cap574mUSD
Jul 10, Last price  
5.44CNY
1D
4.02%
1Q
-25.58%
Jan 2017
-62.40%
IPO
-17.00%
Name

Zhejiang Yatai Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002370 chart
P/E
42.12
P/S
12.55
EPS
0.13
Div Yield, %
—
Shrs. gr., 5y
6.89%
Rev. gr., 5y
0.50%
Revenues
323m
-20.25%
415,431,739429,667,249435,223,960420,339,304316,044,643313,637,217375,601,838463,145,518862,874,5461,082,951,0501,309,709,236707,990,164514,885,286315,134,248315,134,248373,440,356373,440,356420,643,618405,174,660323,136,959
Net income
96m
+181.27%
41,609,95148,152,15342,046,48543,794,836-25,717,5235,480,18640,567,98155,499,288125,290,562202,152,124207,785,783-1,920,673,75927,274,9930-228,280,3110-132,689,752-11,876,96434,239,78396,307,827
CFO
29m
+18.66%
023,084,220068,261,789048,789,691031,122,81773,312,902100,934,5360127,593,60636,994,829017,806,768012,040,71914,651,74524,353,10828,896,362
Dividend
Jun 10, 20190.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Zhejiang Yatai Pharmaceutical Co., Ltd. operates across the entire pharmaceutical value chain, encompassing the research, development, manufacturing, sales, and global distribution of its medicinal products. The company's diverse product portfolio includes a variety of dosage forms, such as tablets, capsules, transdermal patches, powder for injection, and lozenges. Beyond finished pharmaceutical goods, Zhejiang Yatai also supplies chemical agents, essential raw materials, and diagnostic reagents. Furthermore, it extends its expertise to providing outsourced research and development services for the pharmaceutical industry. Established in 1989, Zhejiang Yatai Pharmaceutical Co., Ltd. is headquartered in Shaoxing, China.
URL
http://www.ytyaoye.com/
IPO date
Mar 16, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT